Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study

ClinicalTrials.gov ID: NCT03216902

Public ClinicalTrials.gov record NCT03216902. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIb, Randomized, Observer-Masked, Placebo- and Active-Controlled, Parallel-Group, Multinational and Multicenter Study Assessing the Safety and Efficacy of DE-126 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study

Study identification

NCT ID
NCT03216902
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Santen Inc.
Industry
Enrollment
241 participants

Conditions and interventions

Interventions

  • Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution Drug
  • Topical ultra-low dose of DE-126 Ophthalmic Solution Drug
  • Topical low dose of DE-126 Ophthalmic Solution Drug
  • Topical medium dose of DE-126 Ophthalmic Solution Drug
  • Topical high dose of DE-126 Ophthalmic Solution Drug
  • 0.005% Latanoprost Ophthalmic Solution Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 24, 2017
Primary completion
Feb 26, 2018
Completion
Feb 26, 2018
Last update posted
Oct 22, 2020

2017 – 2018

United States locations

U.S. sites
12
U.S. states
6
U.S. cities
12
Facility City State ZIP Site status
Sall Research Medical Center, Inc Artesia California 90701
North Valley Eye Medical Group Mission Hills California 91345
Eye Research Foundation, INC Newport Beach California 92657
North Bay Eye Associates, Inc. Petaluma California 94954
Shettle Eye Research, Inc. Largo Florida 33773
Clayton Eye Clinical Research, LLC Morrow Georgia 30260
Coastal Research Associates, LLC Roswell Georgia 30076
Rochester Ophthalmological Group, PC Rochester New York 14618
Mundorf Eye Center Charlotte North Carolina 28204
Cornerstone Health Care, LLC High Point North Carolina 27262
Keystone Research Ltd SMO/Texan Eye, PA Austin Texas 78731
Keystone Research LTD SMO/Medical Center Ophthalmology Assoc. San Antonio Texas 78240

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03216902, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 22, 2020 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03216902 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →